{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:37:07Z","timestamp":1768361827331,"version":"3.49.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,10]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Statin-associated myalgia are common, but rhabdomyolysis remains a rare and severe adverse effect. There are scant reports, both domestically and internationally, on rhabdomyolysis induced by the combination of atorvastatin and ticagrelor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient Concerns:<\/jats:title>\n                    <jats:p>A 57-year-old male patient with acute coronary syndrome underwent emergency percutaneous coronary intervention surgery. He was prescribed ticagrelor (90\u2009mg twice daily) and atorvastatin (40\u2009mg once daily). Three days after treatment initiation, his creatine kinase, creatinine, and myoglobin levels increased markedly, and he developed acute renal failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Rhabdomyolysis was diagnosed based on the medication history, significantly elevated creatine kinase and myoglobin levels, and the onset of acute renal failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Management included immediate drug discontinuation, aggressive fluid resuscitation, continuous renal replacement therapy, and extracorporeal membrane oxygenation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Despite these efforts, the patient died.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case aims to alert clinicians to the potential for this rare but fatal adverse effect, particularly in high-risk patients receiving aggressive statin therapy. It also discusses the rationale for considering alternative lipid-lowering strategies in acute coronary syndrome patients with multiple risk factors for statin-induced myotoxicity to mitigate the risk of rhabdomyolysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045189","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:02:52Z","timestamp":1760331772000},"page":"e45189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Combination of atorvastatin and ticagrelor associated with rhabdomyolysis: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2548-4800","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People\u2019s Hospital Medical Group of Xiangzhou, Zhuhai, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-8632","authenticated-orcid":false,"given":"Ling","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, The People\u2019s Hospital Medical Group of Xiangzhou, Zhuhai, Guangdong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260113","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"R2-20260113","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development.","volume":"2","author":"Gagnier","year":"2013","journal-title":"Glob Adv Health Med"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association.","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R6-20260113","first-page":"146","article-title":"Statin-associated rhabdomyolysis: is there a dose-response relationship?","volume":"27","author":"Holbrook","year":"2011","journal-title":"Can J Cardiol"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy: a genomewide study.","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","article-title":"Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.","volume":"69","author":"Teng","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10557-023-07459-8","article-title":"Rhabdomyolysis with co-administration of statins and antiplatelet therapies: analysis of the WHO pharmacovigilance database.","volume":"38","author":"Roule","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"R12-20260113","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy.","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"R14-20260113","first-page":"237","article-title":"Chinese guidelines for lipid management (2023).","volume":"38","year":"2023","journal-title":"Chin Circ J"},{"key":"R15-20260113","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:02:53Z","timestamp":1768334573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":13,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045189","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}